港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

長風藥業

20.260

-0.120-0.59%

成交量：4.10萬

成交額：83.30萬

市值：83.27億

市盈率：2,651.37

高：20.660

開：20.360

低：20.040

收：20.380

52周最高：48.800

52周最低：18.100

股本：4.11億

香港流通股本：3.02億

量比：0.18

換手率：0.01%

股息：- -

股息率：- -

每股收益(LYR):0.008

淨資產收益率：0.21%

總資產收益率：-0.83%

市淨率：4.90

市盈率(LYR):2,651.49

市銷率: 16.63

資料載入中...

總覽公司新聞資訊公告

長風藥業(02652)4月9日斥資29.68萬港元回購1.3萬股

長風藥業4月9日回購1.3萬股，耗資約29.68萬港元

長風藥業更新3月股份變動月報表，股本維持穩定

長風藥業回購2萬股股份，耗資約45.67萬港元

長風藥業(02652)4月2日耗資約45.67萬港元回購2萬股

長風藥業3月31日回購9500股，總額約21.85萬港元

長風藥業(02652)3月31日斥資21.8萬港元回購9500股

智通财经网

長風藥業(02652)發布年度業績經調整年內利潤3175.1萬元持續向「全球吸入系統平台公司」轉型升級

長風藥業(02652)與京東健康簽署戰略合作

長風藥業與京東健康達成三年戰略合作新品線上首發平台獨家落户

長風藥業預計2025年經調整淨利3000萬元至3500萬元

長風藥業(02652)預計2025年度經調整淨利潤約3000萬元至3500萬元，業務運營穩健，創新研發持續推進

長風藥業：預計2025年度淨利潤將降至約0.02億–0.03億元，按年下滑約86%–91%

長風藥業年度業績預告：主力產品CF017均價下滑拖累盈利

長風藥業(02652)股價顯著上升14.541%，現價港幣$28.2

阿斯达克财经

重大突破！長風藥業(2652.HK)全球創新改良機制肺動脈高壓新藥獲IND受理，精準給藥平台再立里程碑

長風藥業大升逾41%！該公司自主研發的肺動脈高壓新藥IND獲受理，填補國內治療PH-ILD領域空白

老虎资讯综合

港股異動 | 長風藥業(02652)升逾17% 肺動脈高壓新藥IND獲受理填補國內治療PH-ILD領域空白

長風藥業(02652)自主研發的吸入粉霧劑候選藥物ICF001的IND申請獲NMPA受理

全球改良機制！長風藥業(02652)肺動脈高壓新藥IND獲受理精準遞送平台創新轉化再獲里程碑

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02652/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02652","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","market":"HK","secType":"STK","nameCN":"長風藥業","latestPrice":20.26,"timestamp":1780455326208,"preClose":20.38,"halted":0,"volume":41000,"delay":0,"changeRate":-0.005888125613346293,"floatShares":302000000,"shares":411000000,"eps":0.00764133494232698,"marketStatus":"交易中","change":-0.12,"latestTime":"06-03 11:04:55","open":20.36,"high":20.66,"low":20.04,"amount":833000,"amplitude":0.030422,"askPrice":20.26,"askSize":2500,"bidPrice":20.06,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.00764133494232698,"tradingStatus":2,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1780459200000},"marketStatusCode":2,"adr":0,"listingDate":1759852800000,"exchange":"SEHK","adjPreClose":20.38,"openAndCloseTimeList":[[1780450200000,1780459200000],[1780462800000,1780473600000]],"volumeRatio":0.181243,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02652\",,,,,undefined,":{"symbol":"02652","floatShares":302000000,"roa":"-0.83%","roe":"0.21%","lyrEps":0.007641,"volumeRatio":0.181243,"shares":411000000,"dividePrice":0,"high":20.66,"amplitude":0.030422,"preClose":20.38,"low":20.04,"week52Low":18.1,"pbRate":"4.90","psRate":"16.63","week52High":48.8,"institutionHeld":0,"latestPrice":20.26,"committee":-0.428571,"eps":0.00764133494232698,"divideRate":0,"volume":41000,"delay":0,"ttmEps":0.00764133494232698,"open":20.36,"prevYearClose":35,"prevWeekClose":22.22,"prevMonthClose":22.22,"prevQuarterClose":22.16,"fiveDayClose":19.66,"twentyDayClose":22.02,"sixtyDayClose":37.34},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02652\",params:#limit:5,,,undefined,":[{"date":"2026-03-30","symbol":"02652","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02652\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02652\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02652\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02652","date":"2026-06-01","current":2664.532989,"percent":0.839744,"low":-293.764894,"twenty":400.575047,"median":467.575731,"eighty":2963.886694,"high":3595.964728,"avg":1098.551773,"sd":1175.771413,"marketCap":8746652155},"quantilePoints":[{"date":"2025-10-10","current":420.512992,"twenty":-8.053739,"median":420.512992,"eighty":438.465035,"marketCap":12738371726},{"date":"2025-10-17","current":400.969089,"twenty":380.917252,"median":393.18793,"eighty":412.695431,"marketCap":12136883281},{"date":"2025-10-24","current":382.04749,"twenty":383.954109,"median":395.798507,"eighty":407.879105,"marketCap":11568353106},{"date":"2025-10-31","current":411.638127,"twenty":385.87135,"median":395.798507,"eighty":410.009732,"marketCap":12482945126},{"date":"2025-11-07","current":380.629431,"twenty":385.87135,"median":397.412529,"eighty":410.009732,"marketCap":11535394836},{"date":"2025-11-14","current":413.442652,"twenty":386.82146,"median":399.24986,"eighty":411.625005,"marketCap":12565340803},{"date":"2025-11-21","current":474.663516,"twenty":387.596392,"median":401.654037,"eighty":419.1227,"marketCap":14419243545},{"date":"2025-11-28","current":513.213561,"twenty":390.697015,"median":408.734506,"eighty":451.19497,"marketCap":15646939138},{"date":"2025-12-05","current":509.365027,"twenty":391.797785,"median":411.605323,"eighty":487.699676,"marketCap":15556303893},{"date":"2025-12-12","current":478.26383,"twenty":394.588712,"median":413.442652,"eighty":485.541496,"marketCap":14633472306},{"date":"2025-12-19","current":468.273561,"twenty":396.041553,"median":429.606948,"eighty":482.974301,"marketCap":14361566570},{"date":"2025-12-24","current":469.497744,"twenty":396.770692,"median":439.211078,"eighty":482.563912,"marketCap":14443962248},{"date":"2026-01-02","current":452.984556,"twenty":397.492287,"median":451.385447,"eighty":481.570975,"marketCap":13990786022},{"date":"2026-01-09","current":417.797013,"twenty":398.674444,"median":438.955991,"eighty":480.057858,"marketCap":12936121351},{"date":"2026-01-16","current":442.060347,"twenty":399.985866,"median":432.778937,"eighty":478.730146,"marketCap":13731858722},{"date":"2026-01-23","current":466.639698,"twenty":400.772068,"median":439.902936,"eighty":477.371374,"marketCap":14481468286},{"date":"2026-01-30","current":480.840623,"twenty":401.791027,"median":446.916666,"eighty":477.757159,"marketCap":14990389486},{"date":"2026-02-06","current":464.022312,"twenty":403.190746,"median":452.185001,"eighty":477.033593,"marketCap":14502764350},{"date":"2026-02-13","current":452.173894,"twenty":406.744138,"median":454.320794,"eighty":475.6532,"marketCap":14213623359},{"date":"2026-02-20","current":472.094804,"twenty":408.734506,"median":454.916554,"eighty":476.776403,"marketCap":14818441932},{"date":"2026-02-27","current":505.751529,"twenty":411.273773,"median":459.838493,"eighty":479.42962,"marketCap":16048983093},{"date":"2026-03-06","current":445.246344,"twenty":411.572519,"median":460.887466,"eighty":481.94993,"marketCap":14015073071},{"date":"2026-03-13","current":299.287031,"twenty":402.338985,"median":457.528006,"eighty":481.000215,"marketCap":9464083401},{"date":"2026-03-20","current":315.053976,"twenty":397.81132,"median":454.320794,"eighty":480.840623,"marketCap":9924943114},{"date":"2026-03-27","current":299.095644,"twenty":391.175665,"median":451.779671,"eighty":479.42962,"marketCap":9398246299},{"date":"2026-04-02","current":3318.248683,"twenty":389.832113,"median":451.779671,"eighty":480.872541,"marketCap":9381570423},{"date":"2026-04-10","current":3321.445916,"twenty":390.816678,"median":452.984556,"eighty":482.236241,"marketCap":9463036901},{"date":"2026-04-17","current":3317.060015,"twenty":392.419904,"median":455.282385,"eighty":483.410603,"marketCap":9454509433},{"date":"2026-04-24","current":2996.4431,"twenty":394.891161,"median":460.26919,"eighty":490.336167,"marketCap":8541149514},{"date":"2026-04-30","current":3202.871531,"twenty":396.041553,"median":462.144769,"eighty":499.979081,"marketCap":9131900891},{"date":"2026-05-08","current":3148.404437,"twenty":397.173254,"median":463.774025,"eighty":508.169798,"marketCap":9007763175},{"date":"2026-05-15","current":2973.181714,"twenty":398.099028,"median":464.50673,"eighty":512.854422,"marketCap":8528814526},{"date":"2026-05-22","current":2811.882705,"twenty":399.495195,"median":466.720409,"eighty":2921.871357,"marketCap":8047680823},{"date":"2026-05-29","current":3180.044455,"twenty":400.476536,"median":467.247998,"eighty":2926.706614,"marketCap":9133017429},{"date":"2026-06-01","current":3038.815931,"twenty":400.575047,"median":467.575731,"eighty":2963.886694,"marketCap":8746652155}],"updateTime":1780417555810},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02652\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2626186346","title":"長風藥業(02652)4月9日斥資29.68萬港元回購1.3萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186346","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186346?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:56","pubTimestamp":1775732173,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业(02652)发布公告，于2026年4月9日，该公司斥资29.68万港元回购1.3万股股份，每股回购价22.56-23港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426654.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116750366","title":"長風藥業4月9日回購1.3萬股，耗資約29.68萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116750366","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116750366?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:55","pubTimestamp":1775732139,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司（02652）于2026年4月9日发布公告，披露当日在香港联交所场内回购股份1.3万股，占公司已发行股本约0.0043%。回购价格介乎每股22.56港元至23港元，合共耗资约29.68万港元。\n公告显示，该次回购完成后，公司已发行股本变动至301,668,586股，库藏股数量增至555,000股。公司回购授权于2025年12月16日获股东通过，授权总数为30,222,358股，已使用回购股份数量为555,000股，占比约0.1836%。\n公司确认已遵守相关上市规则及法律法规。公告由执行董事及联席公司秘书朱玉玉签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148460462","title":"長風藥業更新3月股份變動月報表，股本維持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1148460462","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148460462?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 16:46","pubTimestamp":1775637990,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司于2026年4月8日披露截至2026年3月31日的股份变动月报表。公告显示，公司本月未进行新增发行或注销操作，已发行股份总数保持在302,223,586股（H股）及109,754,801股（内资股），合计为411,978,387股。公司H股本月通过回购方式使库藏股新增9,500股，对应将已发行股份从上月的301,727,086股减少至301,717,586股，而库藏股由496,500股增至506,000股。上述回购行为未导致股本总数变化。本次月报由执行董事及联席公司秘书朱玉玉签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110793751","title":"長風藥業回購2萬股股份，耗資約45.67萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110793751","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110793751?lang=zh_tw&edition=fundamental","pubTime":"2026-04-02 18:32","pubTimestamp":1775125927,"startTime":"0","endTime":"0","summary":"长风药业于2026年4月2日发布翌日披露报表。公告显示，公司于香港联交所场内回购2万股普通H股，约占回购前公司已发行股本的0.0066%。每股回购价格介乎每股港币22.68元至23.08元，总涉资约45.67万港元。回购完成后，公司已发行股本变动为301,681,586股，同时库藏股数增至542,000股。根据2025年12月16日获股东大会通过的回购授权，长风药业可回购股份总数为30,222,358股。公告强调，公司已遵守香港联交所上市规则及相关法律规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624762570","title":"長風藥業(02652)4月2日耗資約45.67萬港元回購2萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2624762570","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624762570?lang=zh_tw&edition=fundamental","pubTime":"2026-04-02 18:28","pubTimestamp":1775125687,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业(02652)公布，2026年4月2日耗资约45.67万港元回购2万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180214599","title":"長風藥業3月31日回購9500股，總額約21.85萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180214599","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180214599?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 18:41","pubTimestamp":1774953716,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司（股份代号：02652）于2026年3月31日发布公告，披露在香港联交所场内回购9500股H股。此笔回购占该公司已发行股本约0.0031%。\n公告显示，此次回购每股价格区间为22.90港元至23.22港元，总金额约21.85万港元。回购完成后，公司已发行股份（不包括库藏股）为301,717,586股，库藏股数增至506,000股。公司此前获得的回购授权于2025年12月16日获股东大会通过，剩余可回购总数为30,222,358股。\n公司确认已遵守香港联交所证券上市规则及相关法律法规，本次回购由执行董事及联席公司秘书朱玉玉签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623588618","title":"長風藥業(02652)3月31日斥資21.8萬港元回購9500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623588618","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623588618?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 18:38","pubTimestamp":1774953494,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业(02652)发布公告，于2026年3月31日斥资21.8万港元回购9500股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423094.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623390963","title":"長風藥業(02652)發布年度業績 經調整年內利潤3175.1萬元 持續向「全球吸入系統平台公司」轉型升級","url":"https://stock-news.laohu8.com/highlight/detail?id=2623390963","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623390963?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 16:40","pubTimestamp":1774860008,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布截至2025年12月31日止年度业绩，该集团取得收益4.33亿元;毛利3.28亿元;股东应占利润248.5万元;经调整年内利润3175.1万元。2025年是公司于联交所主板上市后的集团首个财政年度。集团收入由2022年的约人民币3.49亿元增长至2023年的约人民币5.56亿元，并于2024年进一步增长至约人民币6.08亿元，期间年复合增长率约为31.9%。其中，集团核心产品 CF017于2024年贡献收入约人民币5.75亿元，占总收入约94.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621747605","title":"長風藥業(02652)與京東健康簽署戰略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2621747605","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621747605?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 08:14","pubTimestamp":1774224870,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布公告，本公司于2026年3月20日与京东健康股份有限公司正式签署战略合作协议。根据战略合作协议，京东健康将作为本公司未来三年多款呼吸及鼻科领域重磅新产品的线上独家首发合作平台。鉴于上述疾病在中国的患者基数较大且具有长期管理的特征，董事会认为，订立战略合作协议符合本公司及其股东的整体利益。本次合作预期有助于提升本公司产品的患者可及性及新产品商业化效率。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","BK1247","LU0051755006.USD","BK1583","06618","86618","LU0456827905.SGD","SGXZ62798434.SGD","SGXZ86797644.SGD","BK1591","BK1589","BK1571","BK1615","BK1142","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168787711","title":"長風藥業與京東健康達成三年戰略合作 新品線上首發平台獨家落户","url":"https://stock-news.laohu8.com/highlight/detail?id=1168787711","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168787711?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 08:05","pubTimestamp":1774224320,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司（股票代码：02652）近日与京东健康签署为期三年的战略合作协议。根据协议内容，京东健康将成为长风药业未来三年内主要新产品的独家线上首发平台。此次合作将依托京东健康的数字化营销能力和全渠道资源，助力长风药业创新产品快速触达终端消费者。双方将通过数据驱动的精准营销策略，共同探索医药健康领域的新零售模式，为患者提供更便捷的药品可及性服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621719212","title":"長風藥業預計2025年經調整淨利3000萬元至3500萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719212","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621719212?lang=zh_tw&edition=fundamental","pubTime":"2026-03-22 16:04","pubTimestamp":1774166640,"startTime":"0","endTime":"0","summary":"3月20日，长风药业（02652）发布公告，预计2025年收入将在4.1亿元至4.5亿元之间，而2024年收入约为6.08亿元，显示出显著下降。根据国际财务报告准则(IFRS)，2025年股东应占溢利预计在200万元至300万元之间，而2024年则为约2109万元。经调整净利润（非国际财务报告准则指标）预计为3000万元至3500万元，较2024年的约5187万元下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603223679733937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621059758","title":"長風藥業(02652)預計2025年度經調整淨利潤約3000萬元至3500萬元，業務運營穩健，創新研發持續推進","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059758","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621059758?lang=zh_tw&edition=fundamental","pubTime":"2026-03-21 00:39","pubTimestamp":1774024786,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 发布公告，集团的整体业务营运维持正常，连续三年保持盈利。集团预期2025年取得收入介于人民币4.10亿元至4.50亿元;根据国际财务报告准则会计准则，股东应占溢利介于人民币200万元至300万元;经调整净利润为介于人民币3000万元至3500万元。公司或会视市场情况及资金安排，在遵守上市规则及适用法规的前提下，考虑进一步回购H股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121931516","title":"長風藥業：預計2025年度淨利潤將降至約0.02億–0.03億元，按年下滑約86%–91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121931516","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121931516?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 22:37","pubTimestamp":1774017454,"startTime":"0","endTime":"0","summary":"长风药业3月20日发布盈利预警，预计2025年度各项业绩指标将出现明显下滑。营业收入：2025年预计为4.10亿–4.50亿元，较2024年的约6.08亿元下降约26%–33%。按国际财务报告准则计，股东应占净利润预计为0.02亿–0.03亿元，较2024年的约0.21亿元下降约86%–91%。剔除上市费用及以股份为基础的薪酬后，2025年调整后净利润预计为0.30亿–0.35亿元，低于2024年的约0.52亿元，降幅约33%–42%。公司指出，目前整体业务运营保持正常，年度审计结果将在2026年3月底正式公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128591258","title":"長風藥業年度業績預告：主力產品CF017均價下滑拖累盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1128591258","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128591258?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 22:32","pubTimestamp":1774017134,"startTime":"0","endTime":"0","summary":"受核心产品CF017及其他主要药品平均售价下调影响，长风药业（CF Pharmtech）预计本财年盈利水平将面临下行压力。产品价格策略的调整虽有助于提升市场渗透率，但短期内将对整体营收规模及利润率产生显著冲击。\n公司表示将持续优化生产成本结构，通过供应链协同与工艺创新抵消部分价格波动带来的负面影响。管理层强调将加速新品研发管线推进，以期通过产品组合升级重塑增长动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02652","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620002554","title":"長風藥業(02652)股價顯著上升14.541%，現價港幣$28.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2620002554","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620002554?lang=zh_tw&edition=fundamental","pubTime":"2026-03-18 09:35","pubTimestamp":1773797700,"startTime":"0","endTime":"0","summary":"[上升股]长风药业(02652) 股价在上午09:35比前收市价显著上升14.541%，现股价为港币$28.2。至目前为止，今日最高价为$28.2，而最低价为$24.62。总成交量为43.4万股，总成交金额为港币$1.165千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190515141040914_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318147/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260318147/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123563012","title":"重大突破！長風藥業(2652.HK)全球創新改良機制肺動脈高壓新藥獲IND受理，精準給藥平台再立里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1123563012","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123563012?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 18:13","pubTimestamp":1773656000,"startTime":"0","endTime":"0","summary":"长风药业股份有限公司（股票代码：2652.HK）近日迎来重大进展，其针对肺动脉高压（PAH）开发的全球创新改良机制新药已获得临床试验申请（IND）受理。这一突破性进展标志着公司在精准药物递送平台技术领域再攀新高，展现了其在创新药研发领域的强大实力。\n该新药凭借全球首创的改良机制，有望为肺动脉高压患者提供更优治疗方案。此次IND的成功受理，不仅验证了长风药业核心技术的先进性，更为后续临床开发奠定了坚实基础。公司精准给药平台持续输出创新成果，本次里程碑事件进一步巩固了其在细分领域的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab62decfe9624416502f0a5b97418c66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02652"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192376225","title":"長風藥業大升逾41%！該公司自主研發的肺動脈高壓新藥IND獲受理，填補國內治療PH-ILD領域空白","url":"https://stock-news.laohu8.com/highlight/detail?id=1192376225","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192376225?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 10:30","pubTimestamp":1773628201,"startTime":"0","endTime":"0","summary":"3月16日，$长风药业$大涨超41%，该公司自主研发的肺动脉高压新药IND获受理，填补国内治疗PH-ILD领域空白消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压及间质性肺疾病相关肺动脉高压的吸入粉雾剂ICF001，其新药临床试验申请已获中国国家药品监督管理局正式受理。ICF001的快速推进，有望使其成为国内首个获批用于治疗PH-ILD的吸入药物，填补这一市场空白，同时为全球数十万计的患者带来生命的$曙光$。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab62decfe9624416502f0a5b97418c66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","BK4580","BK1191","LU0208291251.USD","LU0256863811.USD","LU0256863902.USD","LU1988902786.USD","LU0320765489.SGD","LU2264538146.SGD","02652","BK4588","LU1989772840.SGD","BK4585","LU0417517546.SGD","LU0211331839.USD","LU1989772923.USD","LU0070302665.USD","LU1064131342.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619487098","title":"港股異動 | 長風藥業(02652)升逾17% 肺動脈高壓新藥IND獲受理 填補國內治療PH-ILD領域空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2619487098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619487098?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 10:02","pubTimestamp":1773626554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，长风药业涨超17%，截至发稿，涨16.43%，报26.78港元，成交额1220.58万港元。消息面上，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压及间质性肺疾病相关肺动脉高压的吸入粉雾剂ICF001，其新药临床试验申请已获中国国家药品监督管理局正式受理。ICF001的快速推进，有望使其成为国内首个获批用于治疗PH-ILD的吸入药物，填补这一市场空白，同时为全球数十万计的患者带来生命的曙光。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab62decfe9624416502f0a5b97418c66","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4161","LU1064131342.USD","02652","BK4580","LU1989772923.USD","LU1989772840.SGD","LU0320765489.SGD","LU1988902786.USD","BK1191","LU0256863811.USD","LU2264538146.SGD","BK4585","LU0208291251.USD","LU0211331839.USD","VXUS","LU0070302665.USD","LU0417517546.SGD","BK4588","PH","IND","LU0256863902.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619882190","title":"長風藥業(02652)自主研發的吸入粉霧劑候選藥物ICF001的IND申請獲NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619882190","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619882190?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 21:02","pubTimestamp":1773406944,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长风药业 公布，公司自主研发的吸入粉雾剂候选药物ICF001的新药临床试验申请已获中华人民共和国国家药品监督管理局受理。据悉，ICF001是一款基于前药技术平台自主研发的创新型长效吸入粉雾剂候选药物，专为治疗肺动脉高压及相关严重肺部疾病而设计。ICF001的首发适应症为动脉性肺动脉高压与间质性肺疾病相关肺动脉高压。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02652","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619047168","title":"全球改良機制！長風藥業(02652)肺動脈高壓新藥IND獲受理 精準遞送平台創新轉化再獲里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=2619047168","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619047168?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 13:35","pubTimestamp":1773380142,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月13日，长风药业宣布，公司自主研发的治疗肺动脉高压及间质性肺疾病相关肺动脉高压的吸入粉雾剂ICF001，其新药临床试验申请已获中国国家药品监督管理局正式受理。ICF001 是一款基于前药机制实现长效作用的创新型吸入粉雾剂。该类药物在相关罕见及严重肺部疾病中已确立明确的临床价值及验证的重磅药物潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02652","BK1191","IND"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":8,"pageCount":4,"totalSize":149,"code":"91000000","status":"200"}]}}